ClinicalTrials.gg

Acquired Immunodeficiency Syndrome clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,038 studies for Acquired Immunodeficiency Syndrome across more than 10 countries. 308 are recruiting or about to start. 1,528 of them are mainly about Acquired Immunodeficiency Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 10,222 studies for Acquired Immunodeficiency Syndrome. How that becomes 3,037 here

This page counts the studies the registry files under Acquired Immunodeficiency Syndrome, and those it files under no condition that list Acquired Immunodeficiency Syndromethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 10,222Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −73List Acquired Immunodeficiency Syndrome as a condition, but the registry did not file them under itMost often written as “AIDS Dementia Complex” (8), “AIDS-related Diffuse Large Cell Lymphoma” (8), and “AIDS-related Small Noncleaved Cell Lymphoma” (8). The registry filed 16 of them under no condition at all, and the others under other conditions only, most often HIV Infections (33) and AIDS Dementia Complex (10).
  3. −7,112Match it another way186 name it in the title, 202 in a keyword, and 6,724 by a synonym or other text the search reads.
  4. 3,037The count on this page

Status

Completed
2,241
Status unknown
205
Recruiting
198
Terminated
132
Not yet recruiting
88
Active, not recruiting
82

Phase

Phase 1
509
Phase 2
418
Phase 3
269
Phase 4
211
Early Phase 1
18

Where

United States
1,670
South Africa
166
Canada
123
Uganda
121
Puerto Rico
121
France
109

Who develops what

Add Acquired Immunodeficiency Syndrome to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RitonavirEarlier only
Evidence
  • NCT02016924 · Gilead Sciences · Phase 3 · live · background · “LPV/r” · registered Dec 2013
  • NCT01475838 · Gilead Sciences · Phase 3 · comparator · “RTV” · registered Nov 2011
  • NCT00896051 · Johnson & Johnson · Phase 2 · background · “Ritonavir (rtv) 100 mg” · registered May 2009
Boehringer Ingelheim18% of its industry studiesUS: off-patent, 6 generics marketedEU: off-patent, 1 generic authorized00 studies
TenofovirEarlier only
Evidence
  • NCT04303598 · HeNan Sincere Biotech Co., Ltd · Phase 3 · background · “TDF” · registered Mar 2020
  • NCT02369965 · Frontier Biotechnologies Inc. · Phase 3 · comparator · “tenofovir” · registered Feb 2015
  • NCT00896051 · Johnson & Johnson · Phase 2 · background · “Tenofovir disoproxil fumarate (TDF) 300 mg” · registered May 2009
Gilead Sciences38% of its industry studiesUS: off-patent, 27 generics marketedEU: off-patent, 2 generics authorized00 studies
efavirenzEarlier onlyPhase 4 trial recorded
Evidence
  • NCT04303598 · HeNan Sincere Biotech Co., Ltd · Phase 3 · background · “EFV” · registered Mar 2020
  • NCT00903682 · Johnson & Johnson · Phase 2 · comparator · “efavirenz (EFV)” · registered May 2009
  • NCT00100048 · Merck & Co., Inc · Phase 2 · comparator · “Comparator: efavirenz” · registered Dec 2004
Bristol-Myers Squibb20% of its industry studies00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 22 Jul 2027 est.alimatravir · Merck & Co., Inc · Phase 3 NCT07044297 A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) — primary endpoint: Number of Participants With Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) Infection · 4,390 enrolled
  • 18 Oct 2027 est.alimatravir · Merck & Co., Inc · Phase 3 NCT07071623 A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) — primary endpoint: Number of Participants with Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) Infection · 4,580 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

Coming up

110studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger. 43 (22%) take children under 18. 23 (12%) are for women only and 12 (6%) for men only; 68 (34%) take healthy volunteers.

Recruiting studies that take each age, of 198
AgeWomenMen
1018 (9%)15 (8%)
18159 (80%)156 (79%)
30164 (83%)150 (76%)
40164 (83%)152 (77%)
50165 (83%)159 (80%)
65146 (74%)141 (71%)
75128 (65%)123 (62%)
85122 (62%)117 (59%)

Across all 3,038 studies, recruiting or not: 36% stop at 75 or younger and 32% at 65; 26% take children; 8% are for women only and 7% for men only; 28% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Acquired Immunodeficiency Syndrome studies take

Of 139 phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 114 mo4–28 · 139 studies5 mo2–18 · 76 studies23 mo15–39 · 63 studies
Phase 1/242 mo24–… · 29 studies——
Phase 236 mo18–71 · 86 studies23 mo14–71 · 29 studies47 mo22–65 · 57 studies
Phase 326 mo19–34 · 65 studies22 mo17–27 · 34 studies34 mo20–51 · 31 studies
Phase 431 mo22–47 · 70 studies—32 mo23–49 · 64 studies
Interventional, no phase29 mo17–45 · 648 studies—29 mo17–45 · 642 studies
Observational44 mo19–79 · 177 studies—46 mo22–83 · 165 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 3,038. Browse all 3,038 → or search them.